Pfizer launches new website for migraine, respiratory offerings
By Michael Erman
Aug 27 (Reuters) -Pfizer Inc PFE.N is launching a new website to promote and improve access to its health care offerings for migraine and respiratory illnesses.
The drugmaker said on Tuesday that it launched the site called PfizerForAll to help patients get access to treatments like its COVID-19 drug Paxlovid and its migraine pill Nurtec by offering services like telehealth appointments and diagnostic tests.
It can also help them find vaccines for respiratory illnesses like COVID, flu, respiratory syncytial virus (RSV) and pneumonia.
"These are conditions that consumers engage in deeply," Pfizer Chief U.S. Commercial Officer Aamir Malik said in an interview. "They're engaged in trying to understandtheir own diagnosis, understand what solutions are available to them and navigate care for themselves."
Investors have fled from Pfizer as the market for its COVID-19 vaccine and treatment has shrunk by billions of dollars a year.
The company's 2023 launch of its RSV shot Abrysvo has also been a disappointment, but the company has expressed optimism about the vaccine in the U.S. this year.
Some of these features have existed on the websites for the specific medicine brands or elsewhere, but PfizerForAll brings them onto a single platform and gives the company a place to potentially expand those offerings.
"There's a real-time aspect to having a digital platform where we can add features and add partners to enhance that consumer experience, but we're going to let the consumer and the patient guide us on what it is that they need and what they value, and then we'll grow the platform accordingly from there," Malik said.
Pfizer's new website follows a similar initiative launched by Eli Lilly LLY.N to help patients get its drugs, including the weight-loss medicine Zepbound, called LillyDirect.
Lilly's service enables patients to order their medicines directly from the drugmaker. PfizerForAll does not, making use instead of the existing insurance and pharmacy network for patients to receive their drugs.
Pfizer said among the new offerings on the site are telehealth consultations from UpScriptHealth and delivery options from Instacart CART.O.
Reporting by Michael Erman; Editing by Nick Zieminski
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
